- Home
- BHIL vs UNCY Comparison
BHIL vs UNCY Comparison
Compare BHIL & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHIL
- UNCY
- Stock Information
- Founded
- BHIL 2012
- UNCY 2016
- Country
- BHIL United States
- UNCY United States
- Employees
- BHIL N/A
- UNCY N/A
- Industry
- BHIL Packaged Foods
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- BHIL Consumer Staples
- UNCY Health Care
- Exchange
- BHIL Nasdaq
- UNCY Nasdaq
- Market Cap
- BHIL 27.1M
- UNCY 31.9M
- IPO Year
- BHIL N/A
- UNCY 2021
- Fundamental
- Price
- BHIL $3.90
- UNCY $0.55
- Analyst Decision
- BHIL
- UNCY Strong Buy
- Analyst Count
- BHIL 0
- UNCY 4
- Target Price
- BHIL N/A
- UNCY $5.50
- AVG Volume (30 Days)
- BHIL 14.9K
- UNCY 1.9M
- Earning Date
- BHIL 11-12-2024
- UNCY 11-13-2024
- Dividend Yield
- BHIL N/A
- UNCY N/A
- EPS Growth
- BHIL N/A
- UNCY N/A
- EPS
- BHIL N/A
- UNCY N/A
- Revenue
- BHIL $466,725,000.00
- UNCY N/A
- Revenue This Year
- BHIL N/A
- UNCY N/A
- Revenue Next Year
- BHIL N/A
- UNCY N/A
- P/E Ratio
- BHIL N/A
- UNCY N/A
- Revenue Growth
- BHIL 139.60
- UNCY N/A
- 52 Week Low
- BHIL $3.90
- UNCY $0.20
- 52 Week High
- BHIL $11.03
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- BHIL 12.42
- UNCY 60.92
- Support Level
- BHIL $5.26
- UNCY $0.41
- Resistance Level
- BHIL $7.45
- UNCY $0.55
- Average True Range (ATR)
- BHIL 0.43
- UNCY 0.06
- MACD
- BHIL -0.29
- UNCY 0.00
- Stochastic Oscillator
- BHIL 0.00
- UNCY 67.04
About BHIL Benson Hill Inc.
Benson Hill Inc is an ag-tech company specializing in soy protein innovation. The company has one business segment Ingredient. The company focuses on seed innovation through proprietary germplasm and the CropOS platform. This platform integrates protein, genomic, and strategic data for predictive breeding using AI and ML. They operate a Crop Accelerator for rapid prototyping. Benson Hill is developing a seed portfolio for protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company's revenue can be disaggregated into product categories: Proprietary and Non-Proprietary. Proprietary revenue is defined as any sale of a proprietary bean. Non-Proprietary revenue is all other revenue from non-Proprietary sources.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.